Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Background Seasonal epidemics of respiratory syncytial virus (RSV) cause a clinically
significant burden of disease among young children. Non-pharmaceutical interventions …

Background Nirsevimab is an extended half-life monoclonal antibody to the respiratory
syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire …

Background Lower respiratory infections (LRIs) cause a substantial mortality, morbidity and
economic burden. The present study reported the global, regional and national burden of …

Background Respiratory syncytial virus (RSV) causes a considerable disease burden in
young children globally, but reliable estimates of RSV-related costs and health-related …

Background Limited data are available on the economic costs of respiratory syncytial virus
(RSV) infections among infants and young children in the United States. Methods We …

Background Infants and young children born prematurely are at high risk of severe acute
lower respiratory infection (ALRI) caused by respiratory syncytial virus (RSV). In this study …

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness and death
among children worldwide, particularly in children younger than 6 months and in low …

Background Approximately 97% of global deaths due to RSV occur in low-and middle-
income countries (LMICs). Until recently, the only licensed preventive intervention has been …